BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by analysts at HC Wainwright from $53.00 to $56.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.69% from the company’s previous […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by analysts at HC Wainwright from $53.00 to $56.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.69% from the company’s previous […]
